Stempoint Capital LP Invests $14.25 Million in Enliven Therapeutics, Inc. $ELVN

Stempoint Capital LP purchased a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the first quarter, Holdings Channel reports. The fund purchased 363,438 shares of the company’s stock, valued at approximately $14,247,000. Enliven Therapeutics comprises about 2.7% of Stempoint Capital LP’s holdings, making the stock its 10th biggest holding.

A number of other institutional investors have also bought and sold shares of the company. KBC Group NV bought a new position in shares of Enliven Therapeutics in the 1st quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at about $83,000. Finally, Quantbot Technologies LP grew its stake in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ELVN. Guggenheim assumed coverage on Enliven Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price target on the stock. Stifel Nicolaus increased their target price on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Mizuho raised their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Finally, Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $70.50.

Enliven Therapeutics Trading Down 1.5%

Shares of ELVN stock opened at $52.97 on Thursday. The firm has a fifty day simple moving average of $46.25 and a two-hundred day simple moving average of $38.17. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $55.79. The firm has a market capitalization of $3.23 billion, a PE ratio of -31.72 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. On average, equities analysts predict that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In related news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the sale, the director directly owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. This represents a 19.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Friday, July 17th. The shares were sold at an average price of $52.64, for a total value of $316,787.52. Following the transaction, the chief financial officer owned 46,054 shares in the company, valued at approximately $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 32,036 shares of company stock worth $1,430,676. 3.00% of the stock is owned by insiders.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.